Investors are also receiving mixed signals from Wall Street and institutional investors, with some making big bets on a recovery in gold and silver prices by investing in beaten-down gold miners.
Soro dumped holdings on Barrick Gold Corp and bet now on Yamana
Yamana set to take advantage of higher gold prices from present lowest & AUY -Production will continue to grow in Q3
The company has been able to steadily grow gold production, with Q2 ... It will be a key future contributor to Yamana's growing gold production ...
Yamana’s all-in-sustaining-costs were $864 per ounce, which is a 5% increase quarter-over-quarter, but a healthy 6% decrease year-over-year. This highlights the healthy margin Yamana is able to generate per ounce of gold mined and sold, as well as the company’s ability to remain profitable even if gold prices slide lower.
Furthermore, despite the quarter-over-quarter increase, it remains among some of the lowest in the industry and compares favourably to its peers. For the equivalent period Barrick reported all-in-sustaining-costs of $865 per ounce, Goldcorp Inc. $852 per ounce and Newmont Mining Corp $1,063 per ounce.
preliminary operating results for the third quarter 2014 and mid-year highlights from its 2014 exploration program.
The Company achieved record quarterly production in the third quarter in excess of 390,000 gold equivalent ounces ("GEO")(1) at all-in sustaining cash costs(2,3) within annual guidance range of between $825 and $875 per GEO. Significant contribution and increased production was mostly from Chapada, El Penon, Canadian Malartic, Mercedes and Pilar. This increase represents an increase of over 17% over second quarter production levels. Fourth quarter production is expected to increase further with increases coming mostly from Chapada, El Penon, Canadian Malartic, Mercedes, Pilar and Jacobina. Yamana continues to focus on its cornerstone operations from which it is deriving greatest increase in production at lowest cost.
Yamana's focus on exploration at existing operations continues to be a key to unlocking further value and creating value for shareholders. The emphasis of the 2014 program has been infill drilling to do the work necessary to upgrade the significant inferred mineral resource increase of 2013 and will continue to focus on finding higher quality ounces, those with the greatest potential to most quickly generate cash flow. The Company's exploration budget for 2014 is approximately $75 million with approximately $50 million having been spent through the end of August.
The significance of results of exploration to date include the following:
El Peñón - mineral reserves are expected to be replaced at or above reserve grade this year and significant exploration opportunities continue to exist particularly with the recent discovery of new secondary structures oriented parallel to historical north-south targeted trends.
Minera Florida - mineral resources are expected to be upgraded and expanded in support of mineral reserve growth in 2014 with infill drilling intersections at or above reserve grade.
Chapada - the discovery of Santa Cruz co
Don't understand this #$%$ falling 5% everyday.
GOLD PRODUCTION FOR 2014 RECORD HIGH...?
Certainly the stance of the European regulators is well known, and while the perception that Orexigen's Contrave may be the sweet spot in the middle, an approval overseas is not a foregone conclusion. In fact, now that the time for news on the European front is upon us, the street may be more cautious than ever. Approval in Europe would boost this drug in a heart-beat
•Street awaits launch date of anti-obesity pills.
•Street unsure what Orexigen strategy is to launch drug.
•Europe has not been keen on anti-obesity drugs.
With the approval of an anti-obesity drug, it could be very easy for an investor new in the sector to think that Orexigen (NASDAQ:OREX) is a "no-brainer." After all, two thirds of the country is either overweight or obese and a dug that could help combat that has a massive potential market to tap into. The real story is that all of the hype and potential of the market size fizzled when Vivus (NASDAQ:VVUS) launched Qsymia and Arena (NASDAQ:ARNA) launched Belviq. It was not long after the launch of these drugs that the market came to realize that the anti-obesity sector (as large as it is) is simply not clamoring for a prescription drug solution. Whether the issue is consumer sentiment, physician reluctance, insurance coverage, or simply a risk vs. reward ratio that makes sales of these drugs more modest than anticipated is a hotly contested debate.
Certainly the stance of the European regulators is well known, and while the perception that Orexigen's Contrave may be the sweet spot in the middle, an approval overseas is not a foregone conclusion. In fact, now that the time for news on the European front is upon us, the street may be more cautious than ever. Approval in Europe would boost this drug in a heart-beat, but if Contrave has a similar decision to that of Belviq and Qsymia, the bad news could pressure this equity even more than it already has been pressured.
Orexigen's marketing partner Takeda has already announced a commitment of 900 sales reps to the launch of Contrave. The company has also promised a marketing strategy that has a few "surprises." What has the street scratching their heads is what exactly those surprises may be, and more importantly if these initiatives will be able to deliver a sales trajectory that is more impressive than what we have seen relating to Belviq and Qsymia.
President and Chief Executive Offi, was Vice President of Amgen Inc., it will take a while before take off, wait Oct 24 EMA decision and its going to be positive. CONTRAVE could be the only drug in Europe for Obesity.
Under the license, Auxilium will pay VIVUS a one-time license fee of $30 million. Auxilium may make a $15 million regulatory milestone payment to VIVUS if the FDA approves the STENDRA label to reflect a 15 minute or less onset of action efficacy claim and up to $255 million in potential milestone payments based on the achievement of certain sales targets. VIVUS will also receive royalties on product sales.
It is estimated that more than 50 percent of men over 40 years of age experience some degree of ED. Prevalence of the condition increases with age and can be caused by a variety of factors, including medications (anti-hypertensives, histamine receptor antagonists); lifestyle (tobacco, alcohol use); diseases (diabetes, cardiovascular conditions, prostate cancer); prostatectomy, and spinal cord injuries. The market opportunity for ED medical treatments continues to grow, with U.S. sales exceeding $2.9 billion in 2012. About one half of men being treated with currently available PDE5 inhibitors are dissatisfied with the results of that treatment and tend to switch among the products in pursuit of better efficacy or less side effects.
Point to note here is ARNA did not qualify and withdraw their application where as VIVIUS application was refused by EMA
A waiver for naltrexone (hydrochloride) / bupropion (hydrochloride), prolonged-release tablet, oral
use, the details of which are set out in the opinion of the Paediatric Committee of the European
Medicines Agency annexed hereto, together with its appendices, is hereby granted.
This decision is addressed to Orexigen Therapeutics, Inc., 3344 North Torrey Pines Ct., Suite 200
92037 - La Jolla, United States.
The European Medicines Agency,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of
12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC)
No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/20041,
Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of
31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal
products for human and veterinary use and establishing a European Medicines Agency2,
Having regard to the application submitted by Orexigen Therapeutics, Inc. on 5 November 2012 under
Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said
Regulation and a waiver under Article 13 of said Regulation,
Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on
19 July 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said
Regulation and Article 13 of said Regulation,
Having regard to Article 25 of Regulation (EC) No 1901/2006,
(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the
agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver.
(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
(3) It is therefore appropriate to adopt a decision granting a deferral.
(4) It is therefore appropriate to adopt a decision granting a waiver.
1 OJ L 378, 27.12.2006, p.1.
2 OJ L 136, 30.4.2004, p. 1.
European Medicines Agency decision
EMA/473174/2013 Page 3/8
Has adopted this decision:
A paediatric investigation plan for naltrexone (hydrochloride) / bupropion (hydrochloride), prolongedrelease
tablet, oral use, the details of which are set out in the opinion of t
Committee for Medicinal Products for Human Use (CHMP): 20-23 October 2014
20/10/2014 - 23/10/2014
European Medicines Agency, London, UK
The Committee for Medicinal Products for Human Use
Committee for Medicinal Products for Human Use
The committee that is responsible for preparing the Agency's opinions on questions concerning human medicines. Abbreviated as CHMP.
For more information, see Committee for Medicinal Products for Human Use (CHMP).
(CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines